{"id":754138,"date":"2023-05-03T07:17:20","date_gmt":"2023-05-03T11:17:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/study-demonstrates-use-of-decisiondx-melanoma-to-guide-treatment-decisions-resulted-in-earlier-detection-of-melanoma-with-decreased-metastatic-tumor-burden-compared-to-patients-without-surveilla\/"},"modified":"2023-05-03T07:17:20","modified_gmt":"2023-05-03T11:17:20","slug":"study-demonstrates-use-of-decisiondx-melanoma-to-guide-treatment-decisions-resulted-in-earlier-detection-of-melanoma-with-decreased-metastatic-tumor-burden-compared-to-patients-without-surveilla","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/study-demonstrates-use-of-decisiondx-melanoma-to-guide-treatment-decisions-resulted-in-earlier-detection-of-melanoma-with-decreased-metastatic-tumor-burden-compared-to-patients-without-surveilla\/","title":{"rendered":"Study Demonstrates Use of DecisionDx\u00ae-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies"},"content":{"rendered":"

<\/p>\n

Study Demonstrates Use of DecisionDx\u00ae-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies<\/b><\/p>\n

New independent, multi-center study <\/i>found that patients who received high-risk DecisionDx-Melanoma test results received routine imaging, which led to earlier detection of recurrences, when the tumor burden was lower, which could result in better clinical outcomes<\/i><\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE<\/a>)–
\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent, multi-center study in the Archives of Dermatological Research<\/i> providing a direct chain of evidence that use of DecisionDx\u00ae-Melanoma test results to guide radiological surveillance could lead to improved patient outcomes.1<\/sup> The study, authored by Dhillon et al., can be found here<\/a>.<\/p>\n

\n\u201cPublished clinical use data, coupled with improved responses with immunotherapy when the metastatic tumor burden is lower, has previously shown an indirect chain of evidence between the clinical use of our DecisionDx-Melanoma test and improved outcomes due to early detection of metastasis and therefore early treatment intervention,\u201d said Derek Maetzold, president and chief executive officer of Castle Biosciences. \u201cWe believe this study is significant in that it provides a direct chain of evidence between the use of DecisionDx-Melanoma to guide treatment plan decisions, which could result in improved survival compared to patients from the same institution who did not have their treatment plans informed by our test.\u201d<\/p>\n

\nDecisionDx-Melanoma has been validated to inform two clinical decisions in the management of patients with cutaneous melanoma (CM) that are made in the acute post-diagnosis time period:<\/p>\n

\n1) Use of a sentinel lymph node biopsy (SLNB) surgical procedure,2<\/sup> and
\n
2) The subsequent risk-guided follow-up and management plans that are differentiated between patients who have a high versus a low likelihood of metastasis.3<\/sup><\/p>\n

\n\u201cIn melanoma, as in all cancers, treatment plan decisions are guided by the risk of disease recurrence and metastasis,\u201d continued Maetzold. \u201cIn this study, the authors controlled for SLNB (all patients underwent the procedure and were negative) and evaluated the impact of implementing risk-guided metastatic surveillance treatment plans for patients with a high-risk DecisionDx-Melanoma test result versus standard of care under the current guidelines. The direct improvement in melanoma-specific survival is what we would expect based upon indirect chain of evidence analyses.\u201d<\/p>\n

\nThe Dhillon et al. study, conducted at three National Cancer Institute-designated cancer centers, included patients with Stage I or II CM who had a negative SLNB. The experimental group was comprised of patients who had received high-risk DecisionDx-Melanoma test results and thus received routine imaging every six to twelve months. Patients in the control group did not receive DecisionDx-Melanoma testing and had imaging studies driven only by clinical symptoms or physical exam findings.<\/p>\n

\nKey findings of the study include:<\/p>\n